- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Childhood Sexual Abuse Litigation
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Domestic and International Arbitration
- Ediscovery
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Restructuring and Business Bankruptcy
- Wealth Planning, Administration, and Disputes
- Litigation Support Services
-
January 21, 2020Human Rights Campaign Names Robins Kaplan LLP a “Best Place to Work for LGBTQ Equality” for the Twelfth Consecutive Year
-
January 17, 2020Patrick Arenz Named to America's Top 100 List for High-Stakes Litigation
-
January 08, 2020Bremer Bank Employee-Shareholders File Class Action Lawsuit Against Three Trustees of Otto Bremer Trust
-
January 24, 2020Elimination of Bias: Seeing Juveniles with Justice
-
January 28, 2020Boston 1L Diversity Summer Associate Program Reception
-
January 29-30, 2020American Bar Association Tort Trial & Insurance Practice Section Fidelity & Surety Law Midwinter Conference
-
January 10, 2020Top Tips for Trying Your First (or Next) Patent Jury Trial
-
January 2020A Victory for All Involved
-
January 2020Facing the Music: Protecting Photography in the Age of Instagram
Antitrust Plays Whack-a-Mole as Exclusion of Competition by Drug Monopolists Pops Up Again: Gaming the “REMS”
Some brand-name drug manufacturers have used various tactics—some lawful and some arguably unlawful—in an effort to delay generic competition and maintain monopoly profits.
Fall 2016
The pharmaceutical industry is a big business. Top selling drugs, many protected by patents, often sell at prices reflecting the monopoly power that brand-name drug manufacturers may enjoy. Enter the fray, generic competition, offering patients therapeutic equivalents to brand-name drugs at a fraction of the cost--saving consumers hundreds of billions of dollars each year. The first generic drug to come to market is typically offered at a price discount of 20% to 30% off the brand-name, with entry by additional generic competitors driving the discount to as much as 90%.
Reprinted with permission from: NYLitigator, Fall 2016, Vol. 21, No. 2, published by the New York State Bar Association, One Elk Street, Albany, New York, 12207
The articles on our Website include some of the publications and papers authored by our attorneys, both before and after they joined our firm. The content of these articles should not be taken as legal advice.
Related Professionals
Related Publications
Related News
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.